Lawsuit filed for Investors who lost money with shares of Cytokinetics, Incorporated (NASDAQ: CYTK)

An investor, who purchased shares of Cytokinetics, Incorporated (NASDAQ: CYTK), filed a lawsuit over alleged violations of Federal Securities Laws by Cytokinetics, Incorporated in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Cytokinetics, Incorporated (NASDAQ: CYTK) have certain options and for certain investors are short and strict deadlines running. Deadline: November 17, 2025. NASDAQ: CYTK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

San Francisco, CA based Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. Cytokinetics, Incorporated (NASDAQ: CYTK) reported that its annual Total Revenue rose from $7.53 million in 2023 to $18.47 million in 2024, and that its Net Loss increased from $526.24 million in 2023 to $589.52 million in 2024.

On May 1, 2025, Cytokinetics announced that the FDA extended the Prescription Drug

On May 2, 2025, BioPharma Dive published a report on Cytokinetics and stated that, "The Food and Drug Administration has delayed an approval decision on Cytokinetics' experimental hypertrophic obstructive cardiomyopathy drug aficamten so it can have more time to review the company's proposed risk management plan." Following this news, Cytokinetics' stock dropped more than 12% during afternoon trading on that same day.

Shares of Cytokinetics, Incorporated (NASDAQ: CYTK) declined from $110.25 per share on Janaury 08, 2024, to as low as $29.31 per share on May 15, 2025.

The plaintiff claims that between December 27, 2023, to May 6, 2025, the defendants created the false impression that aficamten had been completely and properly submitted as a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA"),and that in truth, the defendants had knowingly or recklessly omitted a Risk Evaluation and Mitigation Strategy ("REMS") from the initial NDA submission, despite prior FDA discussions about safety and risk mitigation, and that the subsequent REMS submission necessitated a three-month delay in the FDA's process for potential approval

Those who purchased shares of Cytokinetics, Incorporated (NASDAQ: CYTK) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.